National Quality Improvement Conference

Quality Management in the Laboratory: Susceptibility Testing For New Antibiotics

Lee Kar Mun, Low Yuan Shen, Ng Kang Ren, Joel Wong, Iris Lim, Pooja Rao, Yang Huina

kar_mun_lee1@ttsh.com.sg



Problem Statement

With the rise of multi-drug resistant pathogens in patients, susceptibility testing ensures that new antibiotics for multi-drug resistant pathogens are used judiciously. (e.g., for Ceftaroline and Eravacycline)

Potential Solutions

Recommended QC Isolates

Clinical Isolates

Susceptibility testing is available from external laboratories, but the long turnaround time and high costs borne by the patient are barriers to timely usage of appropriate antibiotics.

Project Aim

To perform verification study evaluating the accuracy and reproducibility of antimicrobial susceptibility results of Eravacycline and Ceftaroline, using quality control (QC) and clinical isolates.

Lessons Learnt

3 replicates for 5 days In-house testing & External laboratory testing

Compare to known QC ranges

Compare results for reproducibility

Outcomes & Impacts

Local testing for both drugs achieved <u>100%</u> <u>concordance</u> with the expected results using QC strains as recommended by the manufacturer. Testing of clinical isolates reached over <u>90%</u> <u>concordance</u> to the results obtained from external laboratories.

International standards are available for susceptibility testing of new antibiotics.

Laboratory quality measures include standardization of the process and a comparison of performance metrics such as accuracy and reproducibility and comparability with external laboratories.

